Rev Soc Bras Med Trop. 2024 Feb 23;57:e004012024. doi: 10.1590/0037-8682-0045-2024. eCollection 2024.
Visceral leishmaniasis (VL) is a public health problem and is a relevant cause of death in developing countries. This study aimed to evaluate the 20-year survival and predictors of worse prognosis in patients with VL admitted to a reference hospital for the treatment of infectious diseases between 1995 and 2016 in northern Minas Gerais, an area of high endemicity for VL.
This retrospective cohort study was conducted at a hospital in northern Minas Gerais, Brazil. All patients with VL were evaluated over a 20-year period. The medical records were thoroughly analyzed. Cox regression analysis was performed to estimate factors associated with the probability of survival.
The cohort included 972 individuals, mostly male children <10 years old, from urban areas who presented at admission with the classic triad of fever, hepatosplenomegaly, and skin pallor. The mean hemoglobin level was 7.53 mg/dl. The mean interval between symptom onset and hospital admission was 40 days. The instituted therapies ranged from pentavalent antimonates to amphotericin, or both. The probability of survival was reduced to 78% one year after symptom onset. Hemoglobin levels and age were strongly associated with the probability of survival.
Regardless of the mechanism underlying the reduction in hemoglobin and the non-modifiable factors of age, early initiation of drug treatment is the most appropriate strategy for increasing survival in patients with VL, which challenges health systems to reduce the interval between the onset of symptoms and hospital admission.
内脏利什曼病(VL)是一个公共卫生问题,也是发展中国家相关的死亡原因。本研究旨在评估 1995 年至 2016 年期间,巴西米纳斯吉拉斯州北部一家传染病治疗参考医院收治的内脏利什曼病患者 20 年的生存率及其预后不良的预测因素,该地区是内脏利什曼病的高流行区。
这是一项在巴西米纳斯吉拉斯州北部的一家医院进行的回顾性队列研究。对 20 年内所有内脏利什曼病患者进行评估。对病历进行了全面分析。采用 Cox 回归分析来估计与生存率相关的因素。
该队列纳入了 972 名患者,主要为年龄在 10 岁以下的男性儿童,来自城市地区,入院时具有发热、肝脾肿大和皮肤苍白三联征。平均血红蛋白水平为 7.53mg/dl。从症状出现到入院的平均间隔时间为 40 天。所采用的治疗方法从五价锑剂到两性霉素 B,或两者兼用。症状出现后一年的生存率降低至 78%。血红蛋白水平和年龄与生存率密切相关。
无论血红蛋白降低的机制和年龄等不可改变因素如何,早期开始药物治疗是提高内脏利什曼病患者生存率的最合适策略,这对卫生系统提出了挑战,需要减少症状出现和入院之间的时间间隔。